Amplify Treatments, Testing and Advancements ETF's Amplify Treatments, Testing and Advancements ETF has disclosed 52 total holdings in their latest N-PORT filing with the SEC for the
portfolio date of 2024-06-30. The current portfolio value is calculated to be $9.00 Mil, only including common equities, preferred
equities, ETFs, options and warrants for equities. The turnover rate is 1%.
Amplify Treatments, Testing and Advancements ETF's
Total Assets is $10.18 Mil , Total Liabilities is $943,680.00 , Net Assets is $9.24 Mil.
In Amplify Treatments, Testing and Advancements ETF's current portfolio as of 2024-06-30, the top 5 holdings are
Alnylam Pharmaceuticals Inc (ALNY), Labcorp Holdings Inc (LH), Quest Diagnostics Inc (DGX), BioNTech SE (BNTX) and Moderna Inc (MRNA),
not including call and put options.
Amplify Treatments, Testing and Advancements ETF did not buy any new stocks in the current portfolio.
Please visit the "Current Portfolio" tab to see the ETF's current and past N-PORT holdings for Amplify Treatments, Testing and Advancements ETF, as well as holding map,
valuations for each stock, which positions are undervalued, have low PE Ratios, are considered high quality and recently traded at 52-week lows, etc.
Please visit the "Stock Picks" tab to see the ETF's latest trades and stock picks for Amplify Treatments, Testing and Advancements ETF, which include data from form N-PORT.
Please visit the "Summary" page to see the top 10 holdings, recent stock picks, performance, sector / industry breakdown details, as well as past holding history summary for Amplify Treatments, Testing and Advancements ETF.